Deferred Prosecution Agreements: How an Effective Compliance Program Can Help You Plan for the Unpredictable

by Baker Donelson
Contact

During the past several years, prosecutors have increasingly used Deferred Prosecution Agreements (DPAs) against corporations in enforcing white collar criminal statutes. DPAs have enabled companies to avoid the costs and consequences associated with a lengthy criminal investigation and trial. Simultaneously, DPAs have provided the government with a more efficient means to hold corporate wrongdoers accountable and to influence changes in corporate compliance culture. Usually, when a corporation enters into a DPA with the government, a criminal charge is filed; however, no conviction is imposed provided that the company abides by certain terms and conditions and commits no additional crimes during a deferred prosecution period. A corporation that successfully completes this period of pretrial diversion avoids having a criminal conviction on its record.

Historically, there have been few reported cases where courts strenuously objected to proposed DPAs or where the government alleged that a company breached a DPA. Two cases resolved during the past year, however, may presage that corporations may no longer assume that agreeing to a DPA will result in uncritical judicial review and reduced government scrutiny. 

On December 19, 2012, North Carolina-based non-profit WakeMed Health and Hospitals (WakeMed) was charged in a criminal information based on evidence that its cardiac center personnel falsely classified patients for inpatient hospital stays and then fraudulently billed Medicare for associated services. On that date, WakeMed and the U.S. Department of Justice entered into a global settlement that included a civil agreement to resolve False Claims Act allegations related to overbilling Medicare, a two-year DPA, and a five-year Corporate Integrity Agreement (CIA). WakeMed agreed to pay $8 million — a figure representing a multiple of the underlying overpayment amount plus damages— and to submit to an independent monitor’s review. Under the settlement, WakeMed would not be excluded from participation in Medicare.

When WakeMed attempted to admit guilt before a North Carolina federal judge on January 17, 2013, the court refused to accept the DPA, calling it a “slap on the hand.” After reviewing supplemental briefs, the judge subsequently agreed to defer prosecution under an agreement that imposes a five-year CIA and prohibits the hospital from making public statements contradicting the underlying statement of facts. While the judge ultimately accepted the DPA to protect WakeMed’s health care providers, employees, and patients, the judge’s order also left open the possibility that the court might conduct a hearing in a year to examine how the DPA is proceeding.

In September 2010, global medical device manufacturer Wright Medical Group, Inc. (Wright) entered into a one-year DPA with the U.S. Attorney’s Office for the District of New Jersey to resolve a criminal complaint that its subsidiary, Wright Medical Technology, Inc. (WMT), conspired to violate the federal Antikickback Statute. Specifically, WMT was charged with entering into financial arrangements with orthopedic surgeons that involved the offer and solicitation of payments from Wright in exchange for the surgeons’ use of Wright’s hip and knee joint products. As part of the global settlement, Wright and the government agreed to a five-year CIA, which will be overseen by an independent monitor, and to pay $7.9 million in civil and administrative claims.

Months after a federal court in New Jersey accepted the settlement, during the pendency of the deferred prosecution period, Wright announced in a May 2011 Securities and Exchange Commission 8-K filing that it had received a tip through its compliance program concerning potential violations of the terms of the DPA. The company hired outside counsel to conduct an investigation, which unearthed some additional issues relating to physician kickbacks. Wright, consistent with the terms of the DPA, provided written notice to the monitor and the government that it had found “credible evidence of wrongdoing.” In response to Wright’s notice, the U.S. Attorney’s Office accused the corporation of intentionally and materially breaching the DPA, which rendered the company vulnerable to criminal and civil litigation as well as exclusion from Medicare. Under the DPA, Wright was given a short period of time to demonstrate to the government that no breach had occurred, or if it did, that it was not material and had been cured. Ultimately, Wright faced no further charges from the government, yet it did have to operate under the DPA for another year. In October 2012, Wright received notice that the complaint had been dismissed and the DPA terminated.

The WakeMed and Wright cases illustrate how entering into a DPA with the government may not guarantee that the company’s conduct will escape scrutiny. The WakeMed judge’s pointed review and sharp public commentary should put health care corporations on notice that judges may be inclined to reject settlements unless they are satisfied that the DPAs impose adequate corporate oversight and punishment. The Wright case highlights the need for corporate defendants to quickly investigate and report credible allegations of wrongdoing during a deferred prosecution period.

So what can corporate health care defendants do now to prepare for the unlikely event that they have to enter into a DPA? What steps can they take to increase the likelihood that the DPA will withstand exacting judicial and prosecutorial scrutiny? Health care entities should take proactive steps in the near term — and before a civil investigative demand (CID), grand jury subpoena, or target letter arrives — to ensure that their existing compliance and ethics programs are robust and not just curios sitting on the shelf. This means that higher-level management should actively encourage and support the development of a well-run compliance program that contains adequate reporting systems, routine audits and checks, and protections for those who report wrongdoing. The compliance program should clearly discourage conduct that violates civil, criminal, and administrative laws, with significant punishment for wrongdoers. In addition, entities should routinely assess their business strategies to ensure that marketplace fluctuations do not inadvertently cause changes in employee behavior that could violate the law. If a health care corporation does, regrettably, receive a CID or notice that it is a target of a government investigation, this should trigger a quick and focused response that includes, at minimum, a review of the existing compliance program. Are the corporation’s reporting mechanisms deficient? Did the audit and monitoring systems fail to detect the conduct at issue? Are revisions to training and a review of all claims prior to submission to the government in order? Recognition and correction of deficiencies before beginning negotiations with the government may enable the company to minimize, or possibly eliminate, corporate culpability. It may also go a long way in convincing the judge that the corporation has truly accepted responsibility and that a DPA serves as a more-than-adequate-form of punishment and deterrence.

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Baker Donelson | Attorney Advertising

Written by:

Baker Donelson
Contact
more
less

Baker Donelson on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.